ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2859

Citrulline Reactive B Cells Are Present in the Lungs of Early Untreated RA

Vijay Joshua1, Malena Loberg-Haarhaus 1, Heidi Wähämaa 2, Aase Hensvold 2, Khaled Amara 1, Lena Israelsson 1, Ragnhild Stålesen 1, Magnus Sköld 3, Johan Grunewald 3, Caroline Grönwall 1, Vivianne Malmström 1 and Anca Catrina 4, 1Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden, 2Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, 3Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden., Stockholm, Sweden, 4Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: ACPA, Early Rheumatoid Arthritis and B cells, lungs

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 13, 2019

Title: 6W012: RA – Etiology & Pathogenesis II (2858–2863)

Session Type: ACR Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: Structural changes, increased tissue citrullination, signs of local inflammation and anti-citrullinated protein autoantibodies (ACPA) are present in the pulmonary compartment of early untreated seropositive rheumatoid arthritis (RA). These findings provide evidence of a potential role for the lungs in generation and initiation of RA-associated autoimmunity. Here we aimed to investigate the presence of citrulline-reactive B cells in the lung compartment of early untreated RA patients by single-cell cloning of monoclonal antibodies (mAbs) from lung-derived B cells.

Methods: Bronchoalveolar lavage (BAL) fluid cells were obtained from ACPA positive individuals with arthralgia (n=2) and early untreated ACPA positive RA patients (n=5) at the time of diagnosis.The demographics of the individuals included in the study are shown in Table 1.CD19+ B cells were single cell sorted by flow cytometry. Immunoglobulin heavy and light chain variable regions were PCR amplified, sequenced, and analyzed by V-Quest and IgBLAST towards the IMGT database to annotate variable gene usage. Sequences having high somatic hypermutations (SHM) and Fab N-glycosylation sites were selected to be cloned and expressed as humanIgG1 recombinant mAbs. Citrulline reactivity was determined by CCP2 assay and in-house ELISA against citrullinated and native peptides from vimentin, a-enolase, fibrinogen and filaggrin. Polyreactivity was determined by reactivity against double stranded DNA, bacterial lipopolysaccharides (LPS) and insulin.

Results: Significant numbers of B cells could be retrieved from the BAL. CD19+ B cells [n=6144, median(range): 960 (288-1248)] were single sorted from 5 early RA as well as 2 risk-individuals. PCR amplification and subsequent BCR sequencing from 2 of the early RA patients (n=1536 CD19+ B cells) yielded 192 and 213 paired heavy and light chain sequences. 44 monoclonal antibodies (22 from each patient) were selected for expression based on high number of SHM and predicted Fab N-linked glycosylation. Notably, four of the mAbs (9%; 2 antibodies from each patient) were determined to be ACPAs by CCP2 ELISA. The 4 ACPAs had varying ACPA fine-specificity against citrullinated a-enolase, filaggrin, vimentin and fibrinogen peptides (figure 1) without any native peptide binding (figure 1). All the 4 monoclonal ACPAs were negative in polyreactivity test. Sequence analysis of the heavy chain variable region revealed unique V gene usage of the ACPAs arising from different patients, V4-39 or V3-49.

Conclusion: We demonstrate for the first time that citrulline-reactive B cells are present in the lung compartment of early untreated RA. This provides a strong link between the lung and the adaptive autoreactive response in RA, and support the hypothesis of the lung as one of the key sites of initiation and propagation of disease in RA.


Table_1

Table 1: Demographics of the individuals


Figure_1

Figure 1: Heatmap showing reactivity of the 4 ACPA against various citrullinated antigens.


Disclosure: V. Joshua, None; M. Loberg-Haarhaus, None; H. Wähämaa, None; A. Hensvold, None; K. Amara, None; L. Israelsson, None; R. Stålesen, None; M. Sköld, None; J. Grunewald, None; C. Grönwall, None; V. Malmström, None; A. Catrina, None.

To cite this abstract in AMA style:

Joshua V, Loberg-Haarhaus M, Wähämaa H, Hensvold A, Amara K, Israelsson L, Stålesen R, Sköld M, Grunewald J, Grönwall C, Malmström V, Catrina A. Citrulline Reactive B Cells Are Present in the Lungs of Early Untreated RA [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/citrulline-reactive-b-cells-are-present-in-the-lungs-of-early-untreated-ra/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/citrulline-reactive-b-cells-are-present-in-the-lungs-of-early-untreated-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology